A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma
Authors:
- M.F. KoseMKM.F. Kose
- J. SufliarskyJSJ. Sufliarsky
- S. BeslijaSBS. Beslija
- P. SaipPSP. Saip
- G. TulunayGTG. Tulunay
- K. KrejcyKKK. Krejcy
- T. MinarikTMT. Minarik
- E. FitzthumEFE. Fitzthum
- A. HaydenAHA. Hayden
- A. MelemedAMA. Melemed
- 1 February 2005
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 96 (2) , 374-380
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Managing taxane toxicitiesSupportive Care in Cancer, 2003
- Recurrent Ovarian Cancer: Evidence-Based TreatmentJournal of Clinical Oncology, 2002
- Second-Line Treatment of Ovarian CancerThe Oncologist, 2000
- Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy.Supportive Care in Cancer, 1999
- Global cancer statisticsCA: A Cancer Journal for Clinicians, 1999
- A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancerAnnals of Oncology, 1998
- Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patientsAnnals of Oncology, 1997
- Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and PaclitaxelGynecologic Oncology, 1996
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI: Journal of the National Cancer Institute, 1994
- Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.Journal of Clinical Oncology, 1992